Showing 101-120 of 746 for: Cochrane Systematic Reviews > Pharmacotherapeutics 
- Antiplatelet agents and anticoagulants for hypertension
Cochrane Systematic Reviews, 7-Dec-2011
Elevated systemic blood pressure results in high intravascular pressure but the main complications, coronary heart disease (CHD), ischaemic strokes and peripheral vascular disease (PVD), are related to thrombosis rather than haemorrhage. Some complication
- Antiplatelet agents for preventing pre‐eclampsia and its complications
Cochrane Systematic Reviews, 30-Oct-2019
Pre-eclampsia is associated with deficient intravascular production of prostacyclin, a vasodilator, and excessive production of thromboxane, a vasoconstrictor and stimulant of platelet aggregation. These observations led to the hypotheses that antiplatele
- Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery
Cochrane Systematic Reviews, 19-Feb-2015
Peripheral arterial disease (PAD) may cause occlusions (blockages) in the main arteries of lower limbs. One treatment option is bypass surgery using autologous (the patient's own tissue) vein graft or prosthetic (artificial) graft. A number of factors inf
- Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment
Cochrane Systematic Reviews, 15-Aug-2012
Peripheral arterial disease (PAD) is frequently treated by balloon angioplasty. Restenosis/reocclusion of the dilated segments occurs often, depending on length of occlusion, lower leg outflow, stage of disease and presence of cardiovascular risk factors.
- Antiplatelet and anticoagulation for patients with prosthetic heart valves
Cochrane Systematic Reviews, 9-Jul-2013
Patients with prosthetic heart valves are at increased risk for valve thrombosis and arterial thromboembolism. Oral anticoagulation alone, or the addition of antiplatelet drugs, has been used to minimise this risk. An important issue is the effectiveness
- Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia
Cochrane Systematic Reviews, 30-Apr-2013
Polycythaemia vera and essential thrombocythaemia are chronic Philadelphia-negative myeloproliferative neoplasms that increase the risk of arterial and venous thrombosis, as well as bleeding. In addition to the different therapeutic strategies available,
- Antiplatelet therapy for aneurysmal subarachnoid haemorrhage
Cochrane Systematic Reviews, 21-Jul-2008
Secondary ischaemia is a frequent cause of poor outcome in patients with aneurysmal subarachnoid haemorrhage (SAH). Besides vasospasm, platelet aggregation seems to play a role in the pathogenesis of secondary ischaemia. Experimental studies have suggeste
- Antiplatelet therapy for preventing stroke and other vascular events after carotid endarterectomy
Cochrane Systematic Reviews, 21-Jul-2003
Antiplatelet drugs are effective and safe in a wide variety of patients at high risk of vascular ischaemic events. Among patients undergoing vascular surgical procedures, these agents significantly reduce the risk of graft or native vessel occlusion. In t
- Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks
Cochrane Systematic Reviews, 6-Mar-2011
Non-valvular atrial fibrillation (AF) carries an increased risk of stroke. Antiplatelet therapy (APT) is proven effective for stroke prevention in most patients at high-risk for vascular events, but its value for primary stroke prevention in patients with
- Antiplatelet versus anticoagulation treatment for patients with heart failure in sinus rhythm
Cochrane Systematic Reviews, 15-Sep-2016
Morbidity in patients with chronic heart failure is high, and this predisposes them to thrombotic complications, including stroke and thromboembolism, which in turn contribute to high mortality. Oral anticoagulants (e.g. warfarin) and antiplatelet agents
- Antipsychotic drug treatment for elderly people with late‐onset schizophrenia
Cochrane Systematic Reviews, 15-Feb-2012
Schizophrenia is usually considered an illness of young adulthood. However, onset after the age of 40 years is reported in 23% of patients hospitalised with schizophrenia. At least 0.1% of the world's elderly population have a diagnosis of late-onset schi
- Antipsychotic drugs for non-affective psychosis during pregnancy and postpartum
Cochrane Systematic Reviews, 20-Oct-2008
Antipsychotics are commonly prescribed for women suffering psychotic illnesses during pregnancy and the postpartum period. The potential adverse consequences of these different options are multiple and complex, impacting on the foetus, neonate, infant and
- Antipsychotic medication for challenging behaviour in people with learning disability
Cochrane Systematic Reviews, 11-Nov-2008
The term 'challenging behaviour', in the absence of psychiatric disorder, encompasses a wide range of behaviours that may be harmful to people or property, may be difficult to manage and may limit access to community facilities. Antipsychotic medications
- Antipsychotic medication for childhood‐onset schizophrenia
Cochrane Systematic Reviews, 18-Jul-2007
Childhood-onset schizophrenia is schizophrenia with onset prior to the age of 13 years. Although it is rare, people who suffer from schizophrenia at an early age appear to have a clinically severe form of the illness with poor long-term prognosis. Antipsy
- Antipsychotic medication for elderly people with schizophrenia
Cochrane Systematic Reviews, 25-Jan-2006
A large and growing number of older people across the world suffer from schizophrenia. Recommendations for their treatment are largely based on data extrapolated from studies of the use of antipsychotic medications in younger populations. In addition most
- Antipsychotic medication versus placebo for people with both schizophrenia and learning disability
Cochrane Systematic Reviews, 17-Dec-2012
Antipsychotic medication is the standard treatment for people with learning disability and schizophrenia.
- Antipsychotic medications for cocaine dependence
Cochrane Systematic Reviews, 19-Mar-2016
Cocaine dependence is a public health problem characterised by recidivism and a host of medical and psychosocial complications. Cocaine dependence remains a disorder for which no pharmacological treatment of proven efficacy exists.
- Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia
Cochrane Systematic Reviews, 6-Feb-2018
Since the 1950s antipsychotic medication has been extensively used to treat people with chronic mental illnesses such as schizophrenia. These drugs, however, have also been associated with a wide range of adverse effects, including movement disorders such
- Antipsychotics for treatment of delirium in hospitalised non‐ICU patients
Cochrane Systematic Reviews, 18-Jun-2018
Guidelines suggest limited and cautious use of antipsychotics for treatment of delirium where nonpharmacological interventions have failed and symptoms remain distressing or dangerous, or both. It is unclear how well these recommendations are supported by
- Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy
Cochrane Systematic Reviews, 19-Jan-2011
Highly active antiretroviral therapy has reduced the morbidity and mortality of patients with HIV/AIDS. A common first-line ART regimen in low-resource settings includes a non-nucleoside reverse transcriptase inhibitor (NNRTI) and two nucleoside reverse t
